Abbott Shines in Q3 2026 with Strong Sales and EPS
Q3 2026: Abbott's Strategic Moves Pay Off When companies start tossing around terms like 'strong third-quarter results,' ears perk up—especially mine. Abbott (NYSE: ABT) gave us something to chew on with their Q3 2026 earnings, flexing a solid 14.5% reported sales growth. Hey, let’s not forget about the substantial comparable sales growth of 7.0%. They’re waving...
Continue Reading